Crispr Therapeutics AG vs Wells Fargo & Co — how do they compare? Crispr Therapeutics AG trades at $54.07 (market cap $5.23B), while Wells Fargo & Co trades at $87.3 (market cap $264.66B). The key difference: Wells Fargo & Co is far larger — about 50.6× Crispr Therapeutics AG's market cap, and Wells Fargo & Co pays a 2.29% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | WFC | |
|---|---|---|
Market Cap | $5.23B | $264.66B |
Sector | Health | Financials |
52-Week High | $76.78 | $96.40 |
52-Week Low | $44.34 | $73.42 |
Enterprise Value | $3.65B | — |
Dividend Yield | — | 2.29% |
Trailing returns across standard periods
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →